Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial. J of Skin [Internet]. 2017 Oct. 27 [cited 2024 Jul. 3];1(3.1):s129. Available from: https://jofskin.org/33014/index.php/skin/article/view/76